Nuveen’s Decibel Therapeutics, Inc. Common Stock DBTX Stock Holding History

Nuveen’s Portfolio DBTX Stock Details DBTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-11,549	Closed	-$131K	–	3584
2021 Q1	$131K	Buy	+11,549	New	+$181K	﹤0.01%	3268

Other funds holding DBTX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen's DBTX Position: Q2 2021 in Review

Nuveen sold out of Decibel Therapeutics, Inc. Common Stock (DBTX) in Q2 2021, closing a stake of 11,549 shares — an estimated $131K sold.

Nuveen first reported a position in DBTX in Q1 2021 and held it in 1 quarter. The position peaked at $131K in Q1 2021. 46 funds tracked by Wall St. Rank hold DBTX as of Q2 2021.

Nuveen reported no remaining Decibel Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Nuveen sold 11,549 Decibel Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $131K.
Nuveen first reported a position in Decibel Therapeutics, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
Nuveen's Decibel Therapeutics, Inc. Common Stock position peaked at $131K in Q1 2021.
46 funds tracked by Wall St. Rank held Decibel Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Nuveen's 13F filing for Q2 2021, filed 16 Aug 2021.